Drugs & Targets FDA publishes draft guidance to accelerate biosimilar development and lower costs October 31, 2025Vol.51 No.40
Cancer Policy Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA October 24, 2025Vol.51 No.39By Claire Marie Porter
Regulatory NewsTrials & Tribulations Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research October 17, 2025Vol.51 No.38By Edison T. Liu
News AnalysisRegulatory News How animal testing became a MAHA political wedge issueWhile cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough October 17, 2025Vol.51 No.38By Claire Marie Porter and Jacquelyn Cobb
Drugs & Targets FDA requires a boxed warning for immune effector cell-associated enterocolitis following Carvykti treatment October 17, 2025Vol.51 No.38
Drugs & Targets FDA approves Zepzelca + Tecentriq combination as first-line maintenance therapy for ES-SCLC October 03, 2025Vol.51 No.36
Drugs & Targets FDA approves Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer October 03, 2025Vol.51 No.36
Drugs & Targets FDA grants Fast Track Designation to UB-VV111 in vivo CAR T-cell therapy October 03, 2025Vol.51 No.36
Podcast With Anthony Letai’s appointment, NCI is now under new leadership—just in time for a shutdown October 01, 2025Vol.51 No.35
